[10,11]. Our case report clearly shows that EVAR can safely be conducted in haemophilic patients by means of perioperative factor replacement. The choice of this procedure has allowed us to significantly reduce both the haemorrhagic risk associated with the procedure, as well as the cost related to clotting factor replacement therapy. In our opinion, EVAR should be considered as first-line therapy in patients with clinically relevant haemorrhagic disorders. Intraoperative anticoagulant treatment and long-term antiplatelet agents are not contraindicated in this patient population.